Literature DB >> 24036381

A novel polyrotaxane-based delivery system for scutellarin: preparation, characterization, and in vitro evaluation.

Rui-Jian Jiang1, Bo Yang, Zhen-Kun Liu, Yu-Lin Zhao, Xia-Li Liao, Jian Yang, Chuan-Zhu Gao, Fen Wang, Bin Han.   

Abstract

The safe and effective polyrotaxane-based drug delivery system could potentially increase the antiproliferative activity of antitumor medicine. A novel scutellarin-polyrotaxane (SCU-PR), in which scutellarin (SCU) was covalently bound to one of the hydroxyl groups of polyrotaxane (PR), was synthesized, and its characterization was further investigated by NMR, XRD, TG, DSC. The cytotoxicity of SCU-PR was assessed in vitro using human HCT116 and LOVO cell lines in results that the IC50 values of SCU-PR (1.03×10(-6) and 1.01×10(-6)mol/L, respectively), which compared with those of free SCU (7.80×10(-5) and 7.70×10(-5)mol/L, respectively), were lower. The valuable properties of SCU-PR will be potentially useful for its application on human colon cancer chemotherapies.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Characterization; Cyclodextrin; Cytotoxicity; Polyrotaxane; Preparation; Scutellarin

Mesh:

Substances:

Year:  2013        PMID: 24036381     DOI: 10.1016/j.carres.2013.07.009

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  2 in total

1.  Synthesis and Bioactivity Characterization of Scutellarein Sulfonated Derivative.

Authors:  Ting Gu; Yue Zhong; Yu-Ting Lu; Ying Sun; Ze-Xi Dong; Wen-Yu Wu; Zhi-Hao Shi; Nian-Guang Li; Xin Xue; Fang Fang; He-Min Li; Yu-Ping Tang
Journal:  Molecules       Date:  2017-06-21       Impact factor: 4.411

2.  Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis.

Authors:  Xiu-Ying He; Yang Xu; Qing-Jie Xia; Xiao-Ming Zhao; Shan Li; Xiao-Qiong He; Ru-Rong Wang; Ting-Hua Wang
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.